MedTrace Logo

Oral Nemonoxacin in Treating Elderly Patients With CAP

NCT05133752 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-11-24

No results posted yet for this study

Summary

This study was to evaluate the safety and efficacy of oral nemonoxacin in treating elderly patients (aged ≥ 65 years) with community-acquired pneumonia (CAP).

Conditions

  • Community-acquired Pneumonia

Interventions

DRUG

Nemonoxacin

500 mg, oral administration, once daily for 7-10 days.

Sponsors & Collaborators

  • TaiGen Biotechnology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-11
Primary Completion
2020-03-23
Completion
2020-03-23
FDA Drug
Yes

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05133752 on ClinicalTrials.gov